The Role of Intermittent Fasting in Parkinson's Disease

Overview

Journal Front Neurol

Specialty Neurology

Date 2021 Jun 18

PMID 34140926

Citations 5

Authors

Bryan J Neth

Brent A Bauer

Eduardo E Benarroch

Rodolfo Savica

Affiliations

Soon will be listed here.

Citing Articles

The Role of Diet in Parkinson's Disease.

Tosefsky K, Zhu J, Wang Y, Lam J, Cammalleri A, Appel-Cresswell S J Parkinsons Dis. 2024; 14(s1):S21-S34.

PMID: 38251061 PMC: 11380239. DOI: 10.3233/JPD-230264.

Targeting sleep and the circadian system as a novel treatment strategy for Parkinson's disease.

Feigl B, Lewis S, Rawashdeh O J Neurol. 2023; 271(3):1483-1491.

PMID: 37943299 PMC: 10896880. DOI: 10.1007/s00415-023-12073-7.

Protocol for a multicentre cross-sectional, longitudinal ambulatory clinical trial in rheumatoid arthritis and Parkinson's disease patients analysing the relation between the gut microbiome, fasting and immune status in Germany (ExpoBiome).

Hansen B, Laczny C, Aho V, Frachet-Bour A, Habier J, Ostaszewski M BMJ Open. 2023; 13(8):e071380.

PMID: 37597865 PMC: 10441058. DOI: 10.1136/bmjopen-2022-071380.

Dietary Restriction against Parkinson's Disease: What We Know So Far.

Wang Z, Cui Y, Wen L, Yu H, Feng J, Yuan W Nutrients. 2022; 14(19).

PMID: 36235760 PMC: 9571011. DOI: 10.3390/nu14194108.

Scientific Evidences of Calorie Restriction and Intermittent Fasting for Neuroprotection in Traumatic Brain Injury Animal Models: A Review of the Literature.

Xu Y, Liu Z, Xu S, Li C, Li M, Cao S Nutrients. 2022; 14(7).

PMID: 35406044 PMC: 9002547. DOI: 10.3390/nu14071431.

References

Winner B, Jappelli R, Maji S, Desplats P, Boyer L, Aigner S . In vivo demonstration that alpha-synuclein oligomers are toxic. Proc Natl Acad Sci U S A. 2011; 108(10):4194-9. PMC: 3053976. DOI: 10.1073/pnas.1100976108. View

Attwell D, Laughlin S . An energy budget for signaling in the grey matter of the brain. J Cereb Blood Flow Metab. 2001; 21(10):1133-45. DOI: 10.1097/00004647-200110000-00001. View

Maswood N, Young J, Tilmont E, Zhang Z, Gash D, Gerhardt G . Caloric restriction increases neurotrophic factor levels and attenuates neurochemical and behavioral deficits in a primate model of Parkinson's disease. Proc Natl Acad Sci U S A. 2004; 101(52):18171-6. PMC: 539733. DOI: 10.1073/pnas.0405831102. View

Savica R, Grossardt B, Rocca W, Bower J . Parkinson disease with and without Dementia: A prevalence study and future projections. Mov Disord. 2018; 33(4):537-543. PMC: 5892791. DOI: 10.1002/mds.27277. View

Bayliss J, Andrews Z . Ghrelin is the metabolic link connecting calorie restriction to neuroprotection. Neural Regen Res. 2016; 11(8):1228-9. PMC: 5020813. DOI: 10.4103/1673-5374.189171. View

Roberts H, Brown D . Seeking a mechanism for the toxicity of oligomeric α-synuclein. Biomolecules. 2015; 5(2):282-305. PMC: 4496673. DOI: 10.3390/biom5020282. View

Poewe W, Seppi K, Tanner C, Halliday G, Brundin P, Volkmann J . Parkinson disease. Nat Rev Dis Primers. 2017; 3:17013. DOI: 10.1038/nrdp.2017.13. View

Savica R, Grossardt B, Ahlskog J, Rocca W . Metabolic markers or conditions preceding Parkinson's disease: a case-control study. Mov Disord. 2012; 27(8):974-9. PMC: 3539719. DOI: 10.1002/mds.25016. View

Patil S, Jain P, Ghumatkar P, Tambe R, Sathaye S . Neuroprotective effect of metformin in MPTP-induced Parkinson's disease in mice. Neuroscience. 2014; 277:747-54. DOI: 10.1016/j.neuroscience.2014.07.046. View

10.

Lu M, Su C, Qiao C, Bian Y, Ding J, Hu G . Metformin Prevents Dopaminergic Neuron Death in MPTP/P-Induced Mouse Model of Parkinson's Disease via Autophagy and Mitochondrial ROS Clearance. Int J Neuropsychopharmacol. 2016; 19(9). PMC: 5043649. DOI: 10.1093/ijnp/pyw047. View

11.

Athauda D, Maclagan K, Skene S, Bajwa-Joseph M, Letchford D, Chowdhury K . Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial. Lancet. 2017; 390(10103):1664-1675. PMC: 5831666. DOI: 10.1016/S0140-6736(17)31585-4. View

12.

Luth E, Stavrovskaya I, Bartels T, Kristal B, Selkoe D . Soluble, prefibrillar α-synuclein oligomers promote complex I-dependent, Ca2+-induced mitochondrial dysfunction. J Biol Chem. 2014; 289(31):21490-507. PMC: 4118111. DOI: 10.1074/jbc.M113.545749. View

13.

VANITALLIE T, Nonas C, Di Rocco A, Boyar K, Hyams K, Heymsfield S . Treatment of Parkinson disease with diet-induced hyperketonemia: a feasibility study. Neurology. 2005; 64(4):728-30. DOI: 10.1212/01.WNL.0000152046.11390.45. View

14.

Elfawy H, Das B . Crosstalk between mitochondrial dysfunction, oxidative stress, and age related neurodegenerative disease: Etiologies and therapeutic strategies. Life Sci. 2018; 218:165-184. DOI: 10.1016/j.lfs.2018.12.029. View

15.

Singh R, Lakhanpal D, Kumar S, Sharma S, Kataria H, Kaur M . Late-onset intermittent fasting dietary restriction as a potential intervention to retard age-associated brain function impairments in male rats. Age (Dordr). 2011; 34(4):917-33. PMC: 3682068. DOI: 10.1007/s11357-011-9289-2. View

16.

Strauss K, Martins L, Plun-Favreau H, Marx F, Kautzmann S, Berg D . Loss of function mutations in the gene encoding Omi/HtrA2 in Parkinson's disease. Hum Mol Genet. 2005; 14(15):2099-111. DOI: 10.1093/hmg/ddi215. View

17.

Mattson M, Moehl K, Ghena N, Schmaedick M, Cheng A . Intermittent metabolic switching, neuroplasticity and brain health. Nat Rev Neurosci. 2018; 19(2):63-80. PMC: 5913738. DOI: 10.1038/nrn.2017.156. View

18.

Gallegos S, Pacheco C, Peters C, Opazo C, Aguayo L . Features of alpha-synuclein that could explain the progression and irreversibility of Parkinson's disease. Front Neurosci. 2015; 9:59. PMC: 4353246. DOI: 10.3389/fnins.2015.00059. View

19.

Potashkin J, Huang X, Becker C, Chen H, Foltynie T, Marras C . Understanding the links between cardiovascular disease and Parkinson's disease. Mov Disord. 2019; 35(1):55-74. PMC: 6981000. DOI: 10.1002/mds.27836. View

20.

Henchcliffe C, Beal M . Mitochondrial biology and oxidative stress in Parkinson disease pathogenesis. Nat Clin Pract Neurol. 2008; 4(11):600-9. DOI: 10.1038/ncpneuro0924. View